Solara Active Pharma Sciences declared the voting results of its Ninth Annual General Meeting held on September 18, 2026. All five resolutions proposed in the notice were passed by shareholders with the requisite majority through remote e-voting and e-voting at the meeting.

The results were disclosed pursuant to Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The scrutinizer’s report, prepared by Preetham Hebbar & Co., confirmed that no member abstained from voting and all resolutions received sufficient support to be adopted.

Key Resolutions Passed

Shareholders approved several key resolutions during the proceedings. The audited standalone and consolidated financial statements for FY26 were adopted without qualification. Additionally, Mr. Arun Kumar Pillai was reappointed as a Non-Executive Director upon retiring by rotation.

Voting Breakdown on Related-Party Deal

The approval of the material related-party transaction worth ₹480 crore with Strides Pharma Science Limited saw significant participation from public shareholders. Notably, the Promoter and Promoter Group did not vote on this specific resolution as they are interested in the agenda item.

For Resolution 5, a total of 77,94,105 votes were cast in favour, representing 99.8684% of the valid votes polled. Only 10,267 votes were cast against the resolution. The total number of members voting in favour was 157, while 8 members voted against. Three members' votes were declared invalid due to related party status constraints.

Governance and Compliance

The statutory auditors, Deloitte Haskins & Sells LLP, issued clean reports on both standalone and consolidated financial statements. The secretarial auditor certified that the Employee Stock Option Plan (ESOP) schemes were implemented in accordance with SEBI regulations and shareholder approvals.

The voting rights were reckoned as on September 11, 2026. The remote e-voting period remained open from 9:00 am on September 15, 2026, till 5:00 pm on September 17, 2026. The results were declared following the unblocking of votes on September 18, 2026, at 12:43 pm IST.

Solara Active Pharma Sciences has received a rectification order from the Income Tax Department, effectively dropping a tax demand of ₹161.92 crore for Assessment Year 2019-20. The order resolves a dispute initiated by a demand notice received in March 2026.

The Assistant Commissioner of Income Tax, Central Circle 3, Thane, issued the order under Section 154 read with Section 147 of the Income Tax Act, 1961. The authority accepted the company’s application filed on March 18, 2026, which argued that the initial tax computation contained errors requiring correction.

Resolution Details

The rectification order confirms that the tax demand raised pursuant to the notice dated March 17, 2026, was incorrectly computed. Consequently, the pending demand has been reduced to nil. The company stated that there is no impact on its financials or operations as a result of this development.

Regulatory Compliance

The communication does not identify any aberrations, non-compliances, violations, or defaults on the part of Solara Active Pharma Sciences. No penalties, restrictions, or sanctions were imposed. The company confirmed that no further action is required regarding the said demand. The filing was signed by Pooja Jaya Kumar, Company Secretary and Compliance Officer, on August 28, 2026.